Biora Therapeutics, Inc. (NASDAQ: BIOR) is a clinical‐stage biotechnology company focused on developing innovative inhaled therapies for respiratory diseases. Leveraging its proprietary Thermo‐Responsive Inhaled Gel (TRIG™) platform, the company seeks to improve the delivery and efficacy of a wide range of therapeutic molecules, including small molecules, peptides and proteins, by forming a gel upon contact with lung tissues. Biora’s lead product candidate, AB-101, is being developed as an acute treatment for severe exacerbations of chronic obstructive pulmonary disease (COPD), aiming to reduce inflammation and improve respiratory function more effectively than existing inhaled therapies.
The TRIG™ technology is designed to transition from a low‐viscosity aerosol to a bioadhesive gel at body temperature. This unique property enables prolonged residence time in the lungs, which may enhance drug absorption and reduce dosing frequency. Beyond AB-101, Biora’s R&D pipeline includes preclinical programs targeting other inflammatory and infectious pulmonary disorders, as well as exploratory work on inhaled vaccine candidates for diseases such as influenza and tuberculosis. The company holds multiple patents covering its gelation chemistry, formulation processes and delivery devices in key markets around the world.
Founded in 2014 and headquartered in San Diego, California, Biora Therapeutics operates research and development facilities in both the United States and the United Kingdom. The company emerged from collaboration between academic scientists and industry veterans who recognized the unmet need for advanced inhaled drug delivery systems. Since its inception, Biora has established strategic partnerships with contract manufacturing organizations and academic centers to support its preclinical and clinical activities, while also engaging with regulatory authorities in the U.S. and Europe to chart a clear development pathway.
Biora’s leadership team comprises seasoned professionals with deep expertise in respiratory medicine, pharmaceutical development, regulatory affairs and commercialization. The board of directors brings additional experience in biotechnology financing and corporate governance. As Biora advances its clinical programs, it aims to expand its geographic footprint through collaborations and licensing agreements, ultimately addressing serious lung conditions for patients across North America, Europe and other global markets.
AI Generated. May Contain Errors.
Free BIOR Stock Alerts